Ballentine Partners’s Ginkgo Bioworks DNA Stock Holding History

Ballentine Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-252	Closed	-$17K	–	746
2023 Q4	$17K	Sell	252 -50	-17%	-$3.06K	﹤0.01%	680
2023 Q3	$21.9K	Buy	+302	New	+$24.1K	﹤0.01%	600
2023 Q2	–	Sell	-263	Closed	-$14K	–	609
2023 Q1	$14K	Sell	263 -302	-53%	-$19.1K	﹤0.01%	567
2022 Q4	$38.2K	Buy	+565	New	+$52K	﹤0.01%	506

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ballentine Partners's DNA Position: Q1 2024 in Review

Ballentine Partners sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 252 shares — an estimated $17K sold.

Ballentine Partners first reported a position in DNA in Q4 2022 and held it in 4 quarters. The position peaked at $38.2K in Q4 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

Ballentine Partners reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
Ballentine Partners sold 252 Ginkgo Bioworks shares in Q1 2024, an estimated $17K.
Ballentine Partners first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 4 quarters.
Ballentine Partners's Ginkgo Bioworks position peaked at $38.2K in Q4 2022.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Ballentine Partners's 13F filing for Q1 2024, filed 11 Apr 2024.